Species-dependent serum interference in a sandwich ELISA for Apo2L/TRAIL

Journal of Immunological Methods

Volumn 320, Issue 1-2, 2007, Pages 58-69

  DeForge, Laura E ^a   Shih, Danny H ^a   Kennedy, Derek ^a   Totpal, Klara ^a   Chuntharapai, Anan ^a   Bennett, Gregory L ^a   Drummond, Jason H ^a   Siguenza, Patricia ^a   Wong, Wai Lee T ^a  

^a GENENTECH INC   (United States)

Author keywords

Apo2L TRAIL; Immunoassay; Matrix effects; Serum interference

Indexed keywords

3 [(3 CHOLAMIDOPROPYL)DIMETHYLAMMONIO] 1 PROPANESULFONIC ACID; APO2 LIGAND PROTEIN; BOVINE IMMUNOGLOBULIN; DETERGENT; EDETIC ACID; IMMUNOGLOBULIN G; POLYCLONAL ANTIBODY; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOASSAY; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; SENSITIVITY AND SPECIFICITY; SERUM;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; MACACA FASCICULARIS; MICE; PAN TROGLODYTES; RATS; RATS, SPRAGUE-DAWLEY; SERUM; SPECIES SPECIFICITY; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

BOVINAE; MACACA FASCICULARIS; ORYCTOLAGUS CUNICULUS; PAN; PRIMATES; RATTUS; RODENTIA;

EID: 33847368187     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2006.12.001     Document Type: Article

References (34)

1. Almasan A., and Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14 (2003) 337
2. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev., Cancer 2 (2002) 420
3. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., and Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 (1999) 155
4. Bartlett W.A., Browning M.C.K., and Jung R.T. Artefactual increase in serum thyrotropin concentration caused by heterophilic antibodies with specificity for IgG of the family bovidea. Clin. Chem. 32 (1986) 2214
5. Bennett B.D., Bennett G.L., Vitangcol R.V., Jewett J.R.S., Burnier J., Henzel W., and Lowe D.G. Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors. J. Biol. Chem. 266 (1991) 23060
6. Carlsson L.M.S., Rowland A.M., Clark R.G., Gesundheit N., and Wong W.L.T. Ligand-mediated immunofunctional assay for quantitation of growth hormone-binding protein in human blood. J. Clin. Endocrinol. Metab. 73 (1991) 1216
7. Dubois D.Y., Cantraine F., and Malmendier C.L. Comparison of different sandwich enzyme immunoassays for the quantitation of human apolipoproteins A-I and A-II. J. Immunol. Methods 96 (1987) 115
8. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., Dul E., Appelbaum E.R., Eichman C., DiPrinzio R., Dodd R.A., James I.E., Rosenberg M., Lee J.C., and Young P.R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273 (1998) 14363
9. Ezan E., Drieu K., and Dray F. Triton X-100 eliminates plasma proteins interference in a radioimmunoassay for luteinizing hormone-releasing hormone (LHRH) and LHRH analogues. J. Immunol. Methods 122 (1989) 291
10. Hashida S., Nakagawa K., Imagawa M., Inoue S., Yoshitake S., Ishikawa E., Endo Y., Ohtaki S., Ichioka Y., and Nakajima K. Use of inorganic salts to minimize serum interference in a sandwich enzyme immunoassay for human growth hormone using Fab'-horseradish peroxidase conjugate. Clin. Chim. Acta 135 (1983) 263
11. Kelley S.K., and Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr. Opin. Pharmacol. 4 (2004) 333
12. Kelley S.K., Harris L.A., Xie D., DeForge L., Totpal K., Bussiere J., and Fox J.A. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 299 (2001) 31
13. Kim K.J., Burnette W.N., Sublett R.D., Manclark C.R., and Kenimer J.G. Epitopes on the S1 subunit of pertussis toxin recognized by monoclonal antibodies. Infect. Immun. 57 (1989) 944
14. Krummen L.A., Woodruff T.K., DeGuzman G., Cox E.T., Baly D.L., Mann E., Garg S., Wong W.L., Cossum P., and Mather J.P. Identification and characterization of binding proteins for inhibin and activin in human serum and follicular fluids. Endocrinology 132 (1993) 431
15. Kwon B.S., Tan K.B., Ni J., Oh K.-O., Lee Z.H., Kim K.K., Kim Y.-J., Wang S., Gentz R., Yu G.-L., Harrop J., Lyn S.D., Silverman C., Porter T.G., Truneh A., and Young P.R. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J. Biol. Chem. 272 (1997) 14272
16. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., Hillan K., Totpal K., DeForge L., Schow P., Hooley J., Sherwood S., Pai R., Leung S., Khan L., Gliniak B., Bussiere J., Smith C.A., Strom S.S., Kelley S., Fox J.A., Thomas D., and Ashkenazi A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7 (2001) 383
17. Lin Y.S., Nguyen C., Mendoza J.-L., Escandon E., Fei D., Meng Y.G., and Modi N.B. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J. Pharmacol. Exp. Ther. 288 (1999) 371
18. Lub-de Hooge M.N., de Vries E.G.E., de Jong S., and Bijl M. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 64 (2005) 854
19. Marsters S.A., Sheridan J.P., Pitti R.M., Huang A., Skubatch M., Baldwin D., Yuan J., Gurney A., Goddard A.D., Godowski P., and Ashkenazi A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7 (1997) 1003
20. Martinez-Lorenzo M.J., Alava M.A., Gamen S., Kim K.J., Chuntharapai A., Pineiro A., Naval J., and Anel A. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur. J. Immunol. 28 (1998) 2714
21. Maxey K.M., Maddipati K.R., and Birkmeier J. Interference in enzyme immunoassays. J. Clin. Immunoass 15 (1992) 116
22. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., Itoh N., Suda T., and Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature 364 (1993) 806
23. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., and Dixit V.M. The receptor for the cytotoxic ligand TRAIL. Science 276 (1997) 111
24. Pan G., Ni J., Wei Y.-F., Yu G., Gentz R., and Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277 (1997) 815
25. 165 in human plasma. J. Immunol. Methods 219 (1998) 45
26. Selby C. Interference in immunoassay. Ann. Clin. Biochem. 36 (1999) 704
27. Sigel M.B., Sinha Y.N., and VanderLann W.D. Production of antibodies by innoculation into lymph nodes. Methods Enzymol. 93 (1983) 3
28. Tanaka M., Suda T., Yatomi T., Nakamura N., and Nagata S. Lethal effect of recombinant human Fas ligand in mice pretreated with propionibacterium acnes. J. Immunol. 158 (1997) 2303
29. Tracey K.J., Beutler B., Lowry S.F., Merryweather J., Wolpe S., Milsark I.W., Hariri R.J., Fahey T.J., Zentella A., Albert J.D., Shires G.T., and Cerami A. Shock and tissue injury induced by recombinant human cachectin. Science 234 (1986) 470
30. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., Ramakrishnan L., Gray C.L., Baker K., Wood W.I., Goddard A.D., Godowski P., and Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997) 818
31. Ward G., McKinnon L., Badrick T., and Hickman P.E. Heterophilic antibodies remain a problem for the immunoassay laboratory. Am. J. Clin. Pathol. 108 (1997) 417
32. Wood W.G. "Matrix effects" in immunoassays. Scand. J. Clin. Lab. Invest. 51 Suppl. 205 (1991) 105
33. Xiang H., Nguyen C.B., Kelley S.K., Dybdal N., and Escandon E. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab. Dispos. 32 (2004) 1230
34. Yano K., Tsuda E., Washida N., Kobayashi F., Goto M., Harada A., Ikeda K., Higashio K., and Yamada Y. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res. 14 (1999) 518